Robbins Geller Rudman & Dowd LLP recently announced it is investigating potential violations of U.S. federal securities laws ...

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best mid-cap growth stocks to buy right now. On January 14, Bank of ...

By Siddhi Mahatole and Sahil Pandey Jan 13 (Reuters) - The U.S. Food and Drug Administration has extended its review for the expanded use of Travere Therapeutics’ drug to treat a type of rare kidney ...

Lulu’s Fashion Lounge Holdings Inc (NASDAQ: LVLU) shares dipped 10.4% to $10.89 in pre-market trading. Lulu’s Fashion Lounge Holdings shares jumped 79% on Monday after Friedland Enterprises acquired a ...

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

The FDA has extended its review of the company's Filspari. This is a setback for the biotech's leading drug candidate. Travere's leading drug candidate is Filspari, which targets a kidney disorder ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects total U.S. net product sales for the fourth quarter of 2025 to be ...